RightFit
RecruitingPhase 2

A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran

A Phase 2, Randomized, Double-blind, Placebo-controlled, Single Dose Study of the Efficacy, Pharmacodynamics, and Safety of ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years to 75 Years
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study tests how well ALN-AGT01 RVR works, how it acts in the body, and how safe it is. It is for adults with mild to moderate high blood pressure who have already received zilebesiran.

The purpose of this study is to evaluate the efficacy, pharmacodynamics (PD), and safety of ALN-AGT01 RVR in participants with mild to moderate hypertension pretreated with zilebesiran.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Part A: Adults whose average top blood pressure number is 130–170 mmHg when measured sitting down at the clinic.
  • Part A: Taking no blood pressure medicines, or taking up to 2 on a stable treatment plan.
  • Part B: Adults whose average top blood pressure number is 140–170 mmHg when measured sitting down at the clinic.
  • Part B: Have stopped all other blood pressure medicines for at least 3 weeks. Calcium channel blockers and thiazide or thiazide-like diuretics (water pills) are allowed.

Who can't join

  • Both parts: High blood pressure known to be caused by another health condition.
  • Both parts: Blood potassium level above 5 mmol/L.
  • Both parts: An eGFR below 30 mL/min/1.73 m². This test measures how well the kidneys filter blood.
  • Other study rules also apply to who can join.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Part A: Inclusion Criteria * Is an adult participant with a mean seated office systolic blood pressure (SBP) of at least 130 mmHg and no more than than 170 mmHg * Either not taking antihypertensive medication or on stable therapy with up to 2 antihypertensive medications Part B: Inclusion Criteria * Is an adult participant with a mean seated office SBP of at least 140 mmHg and no more than 170 mmHg * Has discontinued all prior antihypertensive medication other than a calcium channel blocker (CCB) and/or thiazide/thiazide-like diuretic (if taking) for at least 3 weeks Both Parts: Exclusion Criteria * Has known secondary hypertension or serum potassium more than 5 mmol/L * Has an estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73m\^2 Note: other protocol defined inclusion / exclusion criteria apply

Study sites (3)

CA

FL

GA